| 5.73 -0.27 (-4.5%) | 03-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 8.05 |
1-year : | 8.9 |
| Resists | First : | 6.89 |
Second : | 7.61 |
| Pivot price | 5.92 |
|||
| Supports | First : | 5.73 |
Second : | 4.76 |
| MAs | MA(5) : | 5.95 |
MA(20) : | 6.02 |
| MA(100) : | 6.62 |
MA(250) : | 7.03 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3  |
| %K %D | K(14,3) : | 19 |
D(3) : | 22.3 |
| RSI | RSI(14): 36.3 |
|||
| 52-week | High : | 10.25 | Low : | 5.59 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CSBR ] has closed above bottom band by 3.2%. Bollinger Bands are 58.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.93 - 5.96 | 5.96 - 5.98 |
| Low: | 5.65 - 5.69 | 5.69 - 5.72 |
| Close: | 5.68 - 5.73 | 5.73 - 5.78 |
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Thu, 05 Mar 2026
Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 12, 2026 - Bitget
Thu, 05 Mar 2026
Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 12, 2026 - Bluefield Daily Telegraph
Thu, 05 Mar 2026
Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 12, 2026 - guardonline.com
Wed, 04 Mar 2026
CSBR SEC Filings - Champions Oncolo 10-K, 10-Q, 8-K Forms - Stock Titan
Mon, 15 Dec 2025
Earnings call transcript: Champions Oncology Q2 2025 sees strong revenue growth - Investing.com
Mon, 15 Dec 2025
Champions Oncology Reports Record Quarterly Service Revenue of $14.9 Million - ACCESS Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 14 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 26.6 (%) |
| Held by Institutions | 47.8 (%) |
| Shares Short | 76 (K) |
| Shares Short P.Month | 77 (K) |
| EPS | 0.17 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.3 |
| Profit Margin | 4.2 % |
| Operating Margin | 1.2 % |
| Return on Assets (ttm) | 5.5 % |
| Return on Equity (ttm) | 98.9 % |
| Qtrly Rev. Growth | 11.5 % |
| Gross Profit (p.s.) | 2.1 |
| Sales Per Share | 4.2 |
| EBITDA (p.s.) | 0.28 |
| Qtrly Earnings Growth | -61.1 % |
| Operating Cash Flow | 6 (M) |
| Levered Free Cash Flow | 5 (M) |
| PE Ratio | 33.7 |
| PEG Ratio | 0 |
| Price to Book value | 19.09 |
| Price to Sales | 1.36 |
| Price to Cash Flow | 12.79 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|